HR+/HER2- ADVANCED BREAST CANCER
Clinical trials for HR+/HER2- ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill combo aims to fight Hard-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combina…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New study observes how palbociclib works in real life for breast cancer
Knowledge-focused OngoingThis study follows over 1,400 patients in Germany and Austria with HR+/HER2- advanced breast cancer who are receiving standard first-line treatment with palbociclib plus hormone therapy. Researchers are collecting real-world data on how long the cancer stays controlled and overal…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Real-World study tracks ribociclib combo in elderly breast cancer
Knowledge-focused OngoingThis study follows 329 older patients (65 years and up) with HR+HER2- advanced breast cancer who are taking ribociclib combined with endocrine therapy as their first or second treatment. Researchers are tracking quality of life, treatment effectiveness, and safety in real-world c…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Ribociclib under the microscope: how does it perform in real life?
Knowledge-focused OngoingThis study follows 376 people with HR+HER2- advanced breast cancer who are taking ribociclib (Risarg) plus endocrine therapy or chemotherapy as part of their routine care in Russia. The goal is to see how long patients stay on treatment before stopping for any reason. Since this …
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Real-world study of advanced breast cancer treatments withdrawn before starting
Knowledge-focused TerminatedThis was an observational study designed to collect medical data from people with HR+/HER2- advanced breast cancer during routine care. The goal was to track treatment effectiveness and side effects in real-world settings. However, the study was withdrawn before enrolling any par…
Matched conditions: HR+/HER2- ADVANCED BREAST CANCER
Sponsor: SciClone Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC